With a deep-rooted focus on pathology, it caters to scientific professionals seeking precision and quality in research and ...

About Akero Therapeutics Akero Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including ...

MICROTIA AWARENESS DAY | NATIONAL LOUISIANA DAY NATIONAL SCRAPPLE DAY National Scrapple Day on November 9th recognizes the ...

First patients dosed in Phase 3 SYNCHRONY Outcomes study of lead candidate efruxifermin (EFX) in patients with compensated ...

The authors concluded that there was evidence for an increased risk for lung cancer due to alcohol and coffee intake, amidst ...

You'll also take classes in chemistry, nutrition, and statistics, plus courses such as Clinical Anatomy and Histology, Survey of Cell Biology for Health Professions, and Contemporary Issues in ...

The former group provides complex real-world microscopy data ... spin-off company is developing virtual staining programs for histology and recently raised $30 million in series B funding.

Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...

Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...

And we were excited to see presentation of data at the World Conference of Lung Cancer and ESMO showing ... to the prior ...

“Histology is not a new modality ... to go beyond that and look at how data collected from prior trials and real-world evidence can help improve the choice of covariates,” says Madhavan.

Additionally, two other studies, SYNCHRONY Real-World and SYNCHRONY Histology, are expected to deliver top-line results in 2026. Another critical aspect is the ongoing Phase IIb SYMMETRY study, which ...